Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial [0.03%]
奥希替尼和贝伐珠单抗联合治疗未经治疗的EGFR突变型NSCLC伴恶性胸膜或心包积液(SPIRAL II)：一项单臂、开放标签、二期临床试验
Makoto Hibino,Osamu Hiranuma,Yoshizumi Takemura et al.
Makoto Hibino et al.
Introduction: First-line treatment of EGFR-mutated NSCLC with erlotinib plus antiangiogenic inhibitor exhibits promising results. However, the efficacy of this combination has not been fully investigated. Therefore, we ev...
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC [0.03%]
Nivolumab与Nivolumab-Ipilimumab组合在EGFR突变型NSCLC中的随机二期试验比较
Gillianne G Y Lai,Jia Chi Yeo,Amit Jain et al.
Gillianne G Y Lai et al.
Introduction: Although immune checkpoint inhibitors (ICIs) have dramatically improved outcomes for nononcogene-addicted NSCLC, monotherapy with programmed cell death protein-1 (PD1) inhibition has been associated with low...
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study [0.03%]
化疗联合免疫检查点抑制剂在由肿瘤诱导的非小细胞肺癌中的作用：加州大学肺癌联盟回顾性研究
David J Benjamin,Shuai Chen,Joanna B Eldredge et al.
David J Benjamin et al.
Introduction: There is a paucity of data on immune checkpoint inhibitors (ICIs) plus doublet chemotherapy (C) in patients with advanced lung cancer whose tumor harbors an actionable mutation. We sought to provide insight ...
Author Reply: In Response to "De Novo KRAS G12C-Mutant SCLC: A Case Report" [0.03%]
作者回复：对“从头KRAS G12C突变型小细胞肺癌一例报告”的回应
Meridith L Balbach,Rosana Eisenberg,Wade T Iams
Meridith L Balbach
Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189 [0.03%]
基线肿瘤负荷为标准的铂类和培美曲塞联合Pembrolizumab用于转移性非鳞状细胞NSCLC患者的疗效：来自KEYNOTE-189的研究事后分析
Shirish Gadgeel,Jhanelle E Gray,Maria Teresa Rizzo et al.
Shirish Gadgeel et al.
Introduction: The aim of this study was to evaluate the efficacy of pemetrexed and platinum plus pembrolizumab by baseline tumor burden. Methods: ...
Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy [0.03%]
主要病理反应和预后评分预测接受新辅助化疗的肺癌患者的生存率
Apar Pataer,Annikka Weissferdt,Arlene M Correa et al.
Apar Pataer et al.
Introduction: Complete pathologic response (CPR) is an acceptable surrogate for survival in clinical trials but it occurs infrequently in patients with NSCLC receiving neoadjuvant chemotherapy (NCT). Therefore, we studied...
Frailty Is Associated With Adverse Postoperative Outcomes After Lung Cancer Resection [0.03%]
脆弱性与肺癌切除术后不良预后相关
Andy Chao Hsuan Lee,Sang Mee Lee,Mark K Ferguson
Andy Chao Hsuan Lee
Introduction: Frailty is an important predictor of outcomes after noncardiac surgery. The 5-factor Modified Frailty Index (mFI-5) is a recently developed frailty metric that has not been adequately evaluated in relation t...
Development of Neuropathic Arthropathy With Entrectinib: Case Report [0.03%]
使用Entrectinib治疗过程中出现神经病性关节病：病例报告
Nicholas P Giustini,Hanna Oh,Keith D Eaton
Nicholas P Giustini
TRK inhibition can lead to on-target neurologic adverse events. Two cases illustrate the development of neuropathic arthropathy as a side effect of entrectinib. After starting entrectinib, both patients developed foot pain, swelling, and se...
Quality of Life After Stereotactic Body Radiation Therapy or Surgery for Early-Stage NSCLC: A Systematic Review [0.03%]
早期肺癌立体定向体部放射治疗和手术后生活质量的系统评价
Austin J Iovoli,Brian Yu,Sung Jun Ma et al.
Austin J Iovoli et al.
Quality of life (QOL) is a key consideration for patients with early-stage NSCLC choosing between treatment options. Currently, it is not well established whether stereotactic body radiation therapy (SBRT) or surgery offers superior QOL in ...
Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement-Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors [0.03%]
EGFR突变型合并EML4-ALK重排的肺癌潜在治疗策略——EGFR酪氨酸激酶抑制剂与ALK抑制剂合用疗法
Ming-Hung Huang,Jih-Hsiang Lee,Pei-Shan Hung et al.
Ming-Hung Huang et al.
Introduction: Although driver gene mutations have been believed to be mutually exclusive, some patients with NSCLC and concomitant EGFR mutations and EML4-ALK rearrangements have been reported. In this study, we reported ...